A Potential New Therapy for Alzheimer’s Disease

The global market for Alzheimer’s Disease (AD) treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023, according to research and consulting firm GlobalData. New innovative technologies and millions of dollars spent on research are all contributing to developments for AD treatment. AZTherapies, Inc. is a company focused on the development and commercialization of novel therapeutics that have potential to fundamentally improve patient outcomes, quality of life, and disease management.
 
AZTherapies, Inc. is a privately held clinical stage pharmaceutical company developing next generation therapies to treat AD, ischemic stroke and other neurodegenerative diseases. The company’s technology platform is built is exclusively patented and licensed from Harvard Medical School and Massachusetts General Hospital. The company’s main product candidate, ALZT-OP1, is a novel dual-action combination drug regimen designed to halt Alzheimer’s while it is still early in development.
 
As of right now, ALZT-OP1 is the only therapy which effects several causes of neuronal damage. AZTherapies is currently conducting a Phase III clinical trial of ALZT-OP1 for early stage Alzheimer’s patients, under the guidance of the FDA. The company expects complete this study in the second half of 2018.
 
AZTherapies second clinical product candidate is ALZT-PSCI, a treatment for post ischemic stroke cognitive impairment (PSCI). The Company’s Investigational New Drug (IND) has been accepted by the FDA, and the company plans to enroll 500 patients for a Phase II clinical trial of to begin in early 2017. Completion of this study is expected in the first half of 2018.
In addition to ALZT-OP1 and ALZT-PSCI, AZTherapies the company is in the process of developing a pipeline of additional disease modifying, small molecule therapies other neurodegenerative conditions such as Parkinson’s disease and cognitive impairment resulting from amyloidosis and stroke.

Leave a Comment